By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mundipharma AG 

St. Alban-Rheinweg 74

Basel    CH-4006  Switzerland
Phone: 41-61-2051112 Fax: 41-61-2051109



Company News
Mundipharma AG Obtains Global (Ex-US) Rights To Orexo (ORXOF)’s Opioid Dependence Treatment Zubsolv (Buprenorphine And Naloxone) 6/30/2016 11:38:55 AM
Mundipharma AG Release: Multinational ADOPT Study Seeks Further Improvement In Management Of Oral Mucositis 6/28/2016 11:31:41 AM
Helsinn Group Signs Exclusive Agreement With Mundipharma AG For The Distribution And Licence Of Anamorelin In Northern Europe Countries 2/16/2016 9:24:55 AM
Mundipharma AG Appointed As Development And Marketing Partner For Flutiform In Mexico, Central And South America 1/28/2016 9:31:57 AM
Skyepharma PLC (SKYEF) Release: SKP-2076 To Be Partnered With Mundipharma AG 12/23/2015 10:04:12 AM
Spectrum Pharma (SPPI) Divests Rights To ZEVALIN (ibritumomab tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma AG 11/18/2015 11:19:41 AM
Mundipharma AG Release: Green Whistle Receives Regulatorry And Marketing Approval In The United Kingdom 10/28/2015 3:02:11 PM
Mundipharma AG: New Study Provides Insights Into Potential Treatment Of Severe Pain In Parkinson’s Disease With Prolonged-Release Oxycodone/Naloxone 10/20/2015 10:52:23 AM
Mundipharma AG And Medical Developments International Announce A New Alliance For The Commercialisation Of Penthrox In Europe 9/14/2015 12:44:26 PM
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Could Bank $1 Billion From Mundipharma AG, Purdue Pharma L.P. Pain Pact 1/12/2015 6:04:11 AM